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Alfonsina Ballester-Lopez, MSc, Judit Núñez-Manchón, MSc, Emma Koehorst, MSc, Ian Linares-Pardo,
Miriam Almendrote, MD, Giuseppe Lucente, MD, Nicolau Guanyabens, MD, Marta Lopez-Osias, BSc,
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We aimed to determine whether 3D imaging reconstruction allows identifying molecular:
clinical associations in myotonic dystrophy type 1 (DM1).
Methods
We obtained myoblasts from 6 patients with DM1 and 6 controls. We measured cytosine-
thymine-guanine (CTG) expansion and detected RNA foci and muscleblind like 1 (MBNL1)
through 3D reconstruction. We studied dystrophia myotonica protein kinase (DMPK) ex-
pression and splicing alterations of MBNL1, insulin receptor, and sarcoplasmic reticulum
Ca(2+)-ATPase 1.
Results
Three-dimensional analysis showed that RNA foci (nuclear and/or cytoplasmic) were present
in 45%–100% of DM1-derived myoblasts we studied (range: 0–6 foci per cell). RNA foci
represented <0.6% of the total myoblast nuclear volume. CTG expansion size was associated
with the number of RNA foci per myoblast (r = 0.876 [95% confidence interval 0.222–0.986])
as well as with the number of cytoplasmic RNA foci (r = 0.943 [0.559–0.994]). Although
MBNL1 colocalized with RNA foci in all DM1 myoblast cell lines, colocalization only
accounted for 1% of total MBNL1 expression, with the absence of DM1 alternative splicing
patterns. The number of RNA foci was associated with DMPK expression (r = 0.967
[0.079–0.999]). On the other hand, the number of cytoplasmic RNA foci was correlated with
the age at disease onset (r = −0.818 [−0.979 to 0.019]).
Conclusions
CTG expansion size modulates RNA foci number in myoblasts derived from patients with
DM1. MBNL1 sequestration plays only a minor role in the pathobiology of the disease in these
cells. Higher number of cytoplasmic RNA foci is related to an early onset of the disease, a
finding that should be corroborated in future studies.
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Myotonic dystrophy type I (DM1) is a multisystemic disorder
with autosomal dominant inheritance caused by a cytosine-
thymine-guanine (CTG) repeat expansion in the 39UTR of the
dystrophia myotonica protein (DMPK) gene.1 The main
pathogenic process underlying DM1 is a toxic RNA gain-of-
function effect of expandedDMPK transcripts forming hairpin-
structured aggregates, called “RNA foci.”2,3 These aggregates
are able to sequester splicing factors, thereby affecting the al-
ternative splicing of some pre-mRNAs such as insulin receptor
(IR), sarcoplasmic/endoplasmic reticulum Ca(2+)-ATPase 1
(ATP2A1),4,5 or muscleblind like 1 (MBNL1).6
Most studies on DM1 have relied on 2D imaging at a single
cell level. Yet, this classic approach does not allow detection of
all RNA foci aggregates nor identification of their location
inside cells. In addition, with this technique, it is not possible
to identify the distribution and sequestration of MBNL1
protein. These limitations have hindered recognition of the
full cascade of molecular events associated with the pheno-
type manifestation of DM1.
Here, we used 3D imaging in whole myoblasts derived from
patients with DM1 with different degrees of affectation in an
attempt to gain insight into the link between DM1 molecular
players and disease phenotype. Thus, we assessed the relationship
between CTG repeat expansion size, RNA foci, MBNL1 coloc-
alization, and splicing defects in DM1 patient-derived myoblasts,
on the one hand, and the clinical characteristics of the patients, on
the other hand. We have obtained new pathophysiology data
related to how DM1 might affect patient-derived myoblasts.
Methods
Standard protocol approvals, registrations,
and patient consents
This study was approved (reference # PI-15-009) by the Ethic
Committee of the University Hospital Germans Trias i Pujol
(Badalona, Spain) and was performed in agreement with the
Declaration of Helsinki for Human Research. All participants
signed a written informed consent to participate in the study.
Participants
Six patients were recruited for this study, with DM1 di-
agnosis confirmed in our laboratory by bidirectional triplet
PCR, as previously described.7 Patient muscle biopsies were
obtained from the left biceps brachialis (n = 5) and vastus
lateralis muscle (n = 1). The control biopsies were obtained
from the hand muscle abductor pollicis longus of healthy
individuals (see supplemental data, links.lww.com/NXG/
A291, for more information on the participants and clinical
data collection).
Myoblast cultures
We extracted muscle cells from the biopsy explants and placed
them on culture plates between 2015 and 2016 in the cell culture
room of our institution (see supplemental data, links.lww.com/
NXG/A291, for more information) and analyzed data from
these myoblasts during 2018 and 2019 as described below.
Expansion repeat sizing in myoblasts
We determined CTG expansion size using long PCR-
southern blotting (see supplemental data, links.lww.com/
NXG/A291, for a detailed description of the protocol).
Three-dimensional imaging of RNA foci
and MBNL1
To detect RNA foci and MBNL1, we performed fluorescence
in situ hybridization and immunostaining. The protocol we
used and the details of 3D imaging can be found in supple-
mental data, links.lww.com/NXG/A291.
Alternative splicing analysis and
DMPK expression
We analyzed alternative splicing and DMPK expression with
reverse transcription (RT) PCR and quantitative PCR (qPCR),
respectively (see supplemental data, links.lww.com/NXG/
A291, for more information on the protocol and primers).
Statistical analysis
Details of the statistical analysis can be found in supplemental
data, links.lww.com/NXG/A291.
Data availability
The data that support the findings of this study are available
from the corresponding author on reasonable request.
Results
Patients’ phenotype
We studied 6 patients with DM1—4 women and 2 men—
with age at disease onset ranging from 15 to 48 years (table 1).
Patients were unrelated except P3 and P4 (who were sisters).
Themajority of patients had cardiac problems, with 3 showing
mild ECG alterations, one (P2) a structural cardiopathy
(valvulopathy), and another one (P5) using a pacemaker. Half
of the patients needed nocturnal mechanical ventilation, and
the other 3 had mild changes in respiratory functional tests
without actual clinical impairment. The muscular impairment
status according to theMuscular Impairment Rating Scale was
Glossary
CI = confidence interval; DM1 = myotonic dystrophy type 1; DMPK = dystrophia myotonica protein kinase; IR = insulin
receptor; MBNL1 = muscleblind like 1; mRS = modified Rankin Scale; qPCR = quantitative PCR; RT-PCR = reverse
transcription PCR.
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variable, with P3 showing minimal signs of muscular impair-
ment on exploration, P2, P4, and P6 presenting with distal
weakness, and P1 and P5 with mild-to-moderate proximal
weakness. Most patients were independent in activities of
daily living (modified Rankin Scale [mRS] score 0–2), yet one
(P5) had severely limitations (mRS score 4). P5 did not to do
the 6-minute walking distance test or the myotonic evaluation
because she died unexpectedly due to respiratory insufficiency
at age 40 years.
CTG expansion correlates with RNA foci
We determine the CTG expansion size and the RNA foci and
MBNL1 staining analyses in the same cells by dividing the cell
lines in different pools. The CTG expansion size in DM1
myoblast cell lines ranged from 195 to 1568 CTG repeats
(table 2).
For the staining of RNA foci and MBNL1, we studied 71 and
84 myoblasts from patients and controls, respectively. There
was a high heterogeneity among DM1 myoblasts with regard
to number of RNA foci. Thus, there was an average of 3 RNA
foci (cytoplasmic and/or nuclear) per cell (range 0–6). On
the other hand, there were no RNA foci in the control myo-
blasts (supplemental figure 1, links.lww.com/NXG/A298).
Heterogeneity was also found for the percentage of cells
carrying RNA foci. Thus, 4 patients had RNA foci in 100% of
their myoblasts, whereas P2 and P6 had RNA foci in 80% and
45% of myoblasts, respectively. Of interest, the cell lines from
P2 and P6 were those carrying the lowest CTG repeat number
(195 and 230, respectively). We found a strong positive
correlation between CTG repeat number and (1) the average
number of total (cytoplasmic + nuclear) RNA foci per myo-
blast (figure 1A), as well as with (2) the average number of
nuclear RNA foci per myoblast (r = 0.830; 95% confidence
interval [CI] 0.056–0.981).
RNA foci in DM1myoblasts are mostly, but not
only, intranuclear
RNA foci were mainly present in the nuclei of DM1 cells.
Nevertheless, all 6 DM1myoblast lines also showed RNA foci
outside this organelle. The prevalence of cytoplasmic RNA
Table 1 Clinical data of patients with DM1
Patient with
DM1 Sex Ageat onset (y)
Biceps
MRC Myotonia (s) Cataracts Cardiopathy Spirometry 6MWD (m) MIRS mRS
P1 F 15a 4 0.52 No LAFB Altered PFT 348 4 2
P2 M 48 5 0.67 Yes Valvulopathy NMV 251 3 2
P3 F 36 5 0.73 Yes None NMV 368 2 1
P4 F 42 5 0.98 Yes 1st-degree AV
block
NMV 338 3 1
P5 F 27 4 NP Yes Pacemaker Altered PFT NP 4 4
P6 M 36 5 0.96 No LAFB Altered PFT 519 3 2
Abbreviations: 6MWD= 6-minute walking distance; AV = atrioventricular; NP = not performed; LAFB = left anterior fascicular block; mRS =modified Rankin Scale;
MIRS = Muscular Impairment Rating Scale; MRC = Medical Research Council Grade; NMV = nocturnal mechanical ventilation; PFT = pulmonary function tests.
a It was not possible to determine the actual age at onset of patient P1, but since at the first visit (age 36 years), she had obvious signs that commonly appear in
the early patient’s life—including oval pallor and temporal atrophy—we considered that the disease onset occurred during adolescence.




























% of cells containing
both nuclear and
cytoplasmic RNA foci
P1 758 11 1 6 2.7 1.6 100 23 36
P2 195 10 0 5 1.8 0.7 80 6 10
P3 899 16 2 6 3.5 0.5 100 14 38
P4 1,568 11 2 6 4.4 0.3 100 8 45
P5 292 12 1 6 3.2 0.9 100 11 25
P6 230 11 0 5 2.3 0.2 45 4 9
Abbreviation: DM1 = myotonic dystrophy type 1.
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foci was, however, heterogeneous—ranging from 4% to 23%
of all RNA foci found (mean = 12%) (table 2). The per-
centage of myoblasts showing cytoplasmic RNA foci also
varied among the different DM1 patient lines, ranging from
10% to 45% of cells. On the other hand, there were no cells
showing cytoplasmic-only RNA foci.
We found a strong, positive correlation between the number
of CTG repeats and the percentage of cells with cytoplasmic
RNA foci (figure 1B). We also found a positive correlation
between the average total number (nuclear + cytoplasmic) of
RNA foci per myoblast and the percentage of cells presenting
RNA foci in the cytoplasm (figure 1C) and also between the
percentage of DM1 myoblasts presenting RNA foci (nuclear
and/or cytoplasmic) and the percentage of RNA foci in the
cytoplasm (figure 1D). We further analyzed the area occupied
by RNA foci (table 2) and found a positive correlation be-
tween this variable and the presence of cytoplasmic foci
(figure 1E). Thus, those cell lines that contained RNA foci
with larger areas had more foci in the cytoplasm.
Higher number of cytoplasmic RNA foci is
associated with an earlier disease onset
When analyzing the relationship between the 3D molecular
findings and the phenotype of patients with DM1, we found
that the number of cytoplasmic RNA foci was inversely re-
lated to the age at disease onset (figure 1F).
RNA foci only represent a small fraction of the
total nucleus volume
The portion of the total nuclear dimension occupied by RNA
foci was analyzed by determining the volume of all the RNA
foci inside the nucleus and by comparing this variable with the
total nuclear volume. RNA foci occupied 0.34%–0.53% of the
total nuclear volume in DM1 myoblasts.
Trapped MBNL1 in RNA foci represent a
negligible fraction of total MBNL1 expression
Given the main role that MBNL1 plays in DM1 disease, we
aimed to analyze the trapping of this protein in the RNA foci.
MBNL1 protein was present in control and DM1 myoblasts.
In all analyzed myoblasts, MBNL1 was located both in the
nucleus and in the cytoplasm (figure 2, B and E). Colocali-
zation of RNA foci together with MBNL1 was found in all
DM1 patients’ lines. The trappedMBNL1 was not only found
in the nucleus (figure 2, A–C), but also in the cytoplasm
(figure 2, D–F), representing 9% of the total cellular coloc-
alization (Video 1). Trapped MBNL1 represented less than
1% of the total MBNL1 expression in DM1 myoblasts.
RNA foci are associated with DMPK transcripts
As RNA foci are the product of DMPK gene transcription, we
aimed to analyze DMPK transcripts in our myoblast cell lines.
To this end, we chose qPCR as it is a more sensitive technique
than RT-PCR and used a probe that was located outside the
Figure 1 Significant correlations of 3D analysis data, CTG expansion size, and phenotype in DM1 myoblasts
(A) Correlation between CTG repeat expansion and RNA foci number. The 95% CI for the Pearson correlation coefficient was 0.222–0.986. (B) Correlation
between CTG repeat expansion and percentage of cells presenting cytoplasmic RNA foci. The 95% CI for the Pearson correlation coefficient was 0.559–0.994.
(C) Correlation between RNA foci number and% of cells presenting cytoplasmic RNA foci. The 95% CI for the Pearson correlation coefficient was 0.263–0.987.
(D) Correlation between % of cells presenting RNA foci and % of cells presenting cytoplasmic RNA foci. The 95% CI for the Pearson correlation coefficient was
0.105–0.983. (E) Correlation between the RNA foci area (μm2) and the presence of cytoplasmic RNA foci. The 95%CI for the Pearson correlation coefficient was
0.085–0.982. (F) Correlation between age at onset of the disease and the presence of cytoplasmic RNA foci. The 95% CI for the Pearson correlation coefficient
was −0.979 to −0.019. rep exp = repeat expansion; n = number; cyto = cytoplasm.
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CTG repeat for detecting expression of both wild-type and
expanded DMPK alleles. We did not find significant differ-
ences between the DMPK expression of patients and controls
myoblasts (figure 3A). In turn, we found a positive correlation
between DMPK expression and (1) total (nuclear and/or
cytoplasmic) RNA foci number (r = 0.967 [95% CI
0.079–0.999], p = 0.033), as well as with the RNA foci that
were present in the nucleus only (r = 0.993 [95% CI
0.682–0.999], p = 0.008).
AbsenceofDM1alternative splicing patterns in
DM1 myoblasts
To study the extent to which was alternative splicing affected
in DM1 myoblasts, we analyzed the expression of inclusion
and exclusion isoforms—MBNL1 exon 7, INSR exon 11, and
ATP2A1 exon 22—that have been previously reported to be
altered in DM1.4,8,9 No differences were found between
controls and patients in the expression ofMBNL1 or ATP2A1
isoforms. However, the expression levels of the INSR exon 11
exclusion isoform—the most expressed isoform in some
DM1 models—showed a tendency of higher expression in
controls than in patients (figure 3B).
Discussion
We studied the quantity and distribution of RNA foci and
MBNL1 protein in DM1 patient–derived myoblasts using a
novel 3D imaging approach. In addition, in the samemyoblast
cultures, we measured CTG expansion, DMPK expression,
and some alternative splicing events. All the molecular data
were correlated with the clinical characteristics of the patients
with DM1. Thus, although more research is needed, the 3D
Figure 2 Confocal microscopy of DM1 myoblasts
MBNL1 protein (green), RNA foci (red), nucleus
(blue). Scale bars: 2.5 μm. (A) XY and XZ volume
slices of individual channels corresponding to
nucleus (blue), MBNL1 protein (green), and RNA
foci (red). DM1 myoblast showing the nuclear
colocalization between the RNA foci and the
MBNL1 protein. (B) Merged image of XY and XZ
volume slices of representative nuclear colocali-
zation between RNA foci and MBNL1 protein in
DM1myoblast.White arrow indicates a single RNA
foci aggregate colocalizing with MBNL1 protein.
(C) Isosurface rendering of nuclear colocalization
between RNA foci and MBNL1 protein in DM1
myoblasts. (D) XY and XZ volume slices of in-
dividual channels corresponding to nucleus (blue),
MBNL1 protein (green), and RNA foci (red). DM1
myoblast showing the cytoplasmic colocalization
between the RNA foci and the MBNL1 protein. (E)
Merged image of XY and XZ volume slices of rep-
resentative cytoplasmic colocalization between
RNA foci and MBNL1 protein in DM1 myoblast.
White arrow indicates a single RNA foci aggregate
colocalizing with MBNL1 protein. (F) Isosurface
rendering of cytoplasmic colocalization between
RNA foci and MBNL1 protein in DM1 myoblasts.
MBNL1 = muscleblind like 1.
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method we used appears as a potential tool to identify po-
tential associations between molecular alterations and clinical
manifestations in patients with DM1.
Our results indicate that the number of RNA foci per DM1
myoblast is regulated by the CTG expansion length. A pre-
vious study showed that RNA foci number differed between
patients with DM1 carrying <500 or >1000 CTG repeats,
respectively.10 In this regard, we have analyzed patients car-
rying CTG expansions within the 500–1,000 range, with RNA
foci related to CTG repeat number. On the other hand, our
data indicate that there are a small number of RNA foci per
DM1myoblast, averaging only 3 per cell (range 0–6), which is
consistent with the findings of previous research in muscle
tissue.3,10–12
Of interest, not all the DM1 myoblasts derived from the same
patient had RNA foci. Two lines of patient-derived myoblasts
who carried the shorter expansions showed RNA foci only in
40% and 80% of the cells. Thus, our results suggest that CTG
expansion not only regulates the amount of RNA foci per
myoblast but also the number ofmyoblasts presenting RNA foci.
In this regard, previous research has suggested that RNA foci can
undergo dynamic changes during the cell cycle13 and travel from
one cell to another.14 Thus, although we cannot discard a certain
effect of the cell cycle phase on our results, we tried to minimize
this potential confounder by seeding the different DM1 myo-
blast cell lines following a well-defined protocol and using
consistently the same treatment method. Based on the expan-
sion sizes that we studied, DM1 myoblasts carrying expansions
close to—or larger than—300 CTG repeats would carry RNA
foci in all their cells. To study whether 300 CTG repeats is an
actual threshold for all patients with DM1 will require a chal-
lenging 3D study in muscle tissue of patients with DM1.
We found both nuclear and cytoplasmic RNA foci. Although
we found myoblasts with cytoplasmic RNA foci in all the
DM1 cell lines that we studied, no myoblast presented
cytoplasmic-only RNA foci. CTG expansion size appears to
regulate the formation of cytoplasmic RNA foci. Thus, larger
CTG expansions will produce a higher number of nuclear foci,
and therefore, more cells will contain cytoplasmic foci because
the latter only appeared in association with nuclear foci. The
presence and origin of cytoplasmic foci have not yet been
studied in depth. Some authors have suggested that cyto-
plasmic RNA foci are a product of the cell cycle as well as of
the breakdown of the nuclear membrane and as such are more
likely to appear in dividing cells.13 However, a study in an
animal model of DM1 expressing CTG expansions in the
heart tissue found RNA foci exclusively in the cytoplasm of
cardiomyocytes, which are highly differentiated, nondividing
cells.15 On the other hand, our results show that cytoplasmic
RNA foci colocalize with MBNL1. The role of cytoplasmic
foci and whether they have a toxic effect should be studied in
future research.
RNA foci represent less than 0.6% of the total nuclear volume
in DM1 myoblasts. Although researchers in the DM1 area are
aware of the small size of RNA foci and of the difficulty to
identify them under the microscope by naked eye, the data
presented here add some information on the impact that RNA
foci have on the nuclear volume. In addition, when analyzing
the area of RNA foci in relation to other molecular findings,
we observed a correlation with the number of cytoplasmic
foci. The fact that scarce data are currently available on cy-
toplasmic RNA foci makes it difficult to interpret our results.
However, as previously described by other authors,16 RNA
foci can fuse or divide randomly with no apparent or known
purpose.
Our analysis of MBNL1 revealed that the sequestration of this
protein inside RNA foci represents less than 1% of the total
MBNL1 myoblast expression. Although there are studies
showing the pathologic role of MBNL1 in DM1,17–21 our
Figure 3 qDMPK expression and splicing analysis
Data are mean ± SD. (A) qDMPK expression in patients with DM1 vs controls. (B) Percentage of the DM1 spliced-related isoform in patients with DM1
compared with controls for MBNL1, IR, and ATP2A1 transcripts measured with RT-PCR. MBNL1 and ATP2A1 showed no significant differences, whereas IR
showed a tendency of higher expression in controls compared with patients (p = 0.057; effect size [Cohen d] = 1.83). DMPK = dystrophiamyotonica protein; IR
= insulin receptor; MNBL1 = muscleblind like 1.
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results are consistent with a previous study by Coleman
et al.22 reporting that only a small proportion of MBNL1
protein (0.2%) was sequestered by RNA foci in DM1 lens
epithelial cells. The study by Coleman and coworkers also
showed that MBNL1 can freely travel from the nucleus to the
cytoplasm or from the cytoplasm to the nucleus depending on
the transcriptional levels and cell requirements. In this con-
text, the low values of sequestration of MBNL1 would suggest
that this phenomenon plays only a minor role in the patho-
physiology of the disease, as 99% of total MBNL1 expression
is free and DM1 myoblasts showed a distribution pattern
similar to that of control myoblasts.
The levels ofDMPK expression were related to the number of
RNA foci per cell. This was an expected finding: indeed, if
there are more RNA foci inside a cell, theoretically there
should also be more DMPK, as for both RNA foci and DMPK
determination, we used a technique, qPCR, which allows
detecting expanded as well as wild-type alleles. How DMPK
expression is affected in DM1 remains to be determined.
DMPK expression levels have been analyzed in several studies
with inconclusive or contradictory results. Some studies
found that DMPK transcripts were increased in myotubes
derived from patients with DM1,23 but other authors found
the opposite result.10,24 In this regard, heterogeneity among
studies with regard to assessment techniques and patient
characteristics limits the ability to gain insight into the alter-
ation of DMPK expression in DM1.
We did not find the expected altered DM1 splicing when
analyzing IR, ATP2A1, and MBNL1 transcripts. As men-
tioned above, the trapped MBNL1 in RNA foci was a minor
event in DM1 myoblasts, and thus, the cascade of molecular
pathomechanisms in which the splicing alteration occurs due
to MBNL1 protein sequestration does not seem to play a
relevant role. These results could also be explained by the fact
that the expression of the aforementioned aberrant isoforms is
related to developmental stages,4,9 and because we used un-
differentiated cells (i.e., myoblasts), the expression pattern
should differ from the pattern of fully differentiated myotubes,
and especially of skeletal muscle fibers.
Our results indicate that an earlier age at disease onset is asso-
ciated with a higher number of cytoplasmic RNA foci. By con-
trast, the age at onset was not correlated with the number of
CTG repeats or RNA foci per myoblast or toDMPK expression
levels. Several studies25–28 have analyzed the possible association
between CTG expansion size and the different DM1-related
symptoms, but CTG instability adds heterogeneity to the dis-
ease, which further complicates to establish these associations.
Our study is limited by the low number of myoblast cell lines
studied and by the complexity of 3D molecular imaging at the
single cell level, which is a highly time-consuming approach.
While keeping this limitation in mind, we were able to eval-
uate the molecular pathologic cascade in 6 patients with DM1
with different clinical manifestations of this disease.
Our 3D imaging study allowed us to analyze the role of
potential DM1 players using a novel approach. Thus, our
results would indicate that CTG expansion determines the
number of RNA foci per myoblast and of myoblasts that
contain RNA foci, as well as the appearance of cytoplasmic
foci. An additional finding is that RNA foci only represent a
small—and in fact negligible—part of the total nucleus
volume and the sequestration of MBNL1 is an infrequent
event. Thus, no DM1 splicing alterations were found. The
DMPK expression levels are related to the number of RNA
foci found per myoblast. Last, we found that cytoplasmic
RNA foci are inversely related to the age at onset of the
patients with DM1 studied. Cytoplasmic RNA foci should be
considered in future studies because the role of these mol-
ecules in the pathobiology of DM1 needs to be clearly
elucidated.
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12. Gudde AEEG, González-Barriga A, van den Broek WJAA, Wieringa B, Wansink DG.
A low absolute number of expanded transcripts is involved in myotonic dystrophy
type 1 manifestation in muscle. Hum Mol Genet 2016;25:1648–1662.
13. Xia G, Ashizawa T. Dynamic changes of nuclear RNA foci in proliferating DM1 cells.
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Ciències de la Salut








Germans Trias i Pujol,
Badalona, Barcelona,
Spain
Collecting the clinical data














Germans Trias i Pujol,
Badalona, Barcelona,
Spain
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Ciències de la Salut














Madrid and Instituto de
Investigación Hospital 12
de Octubre (i+12), Madrid,
Spain
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